After the "glass glue war," GIANT BIOGENE shows its first signs of growth anxiety
Wallstreetcn·
- In mid-2025, a public controversy involving Gigi Biological and Huaxi Biological escalated tensions, impacting Gigi's flagship collagen brand, Kefu Mei, over claims of misrepresented collagen content.
- Despite a slight revenue decline to 55.18 billion yuan and a net profit drop of 7.15%, Kefu Mei saw a 1.6% decrease in sales, while another brand, Keli King, experienced a 9.2% growth, attributed to online expansion.
- Looking ahead to 2026, Gigi Biological aims to regain growth through enhanced medical aesthetics business and new product developments, following a year of challenges that revealed shortcomings in product standards.